From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Last Updated: Monday, July 29, 2024

The monarchE trial—which showed significantly improved invasive disease-free survival and distant relapse-free survival for patients with node-positive, HR+ HER2-, high-risk early breast cancer who were treated with adjuvant abemaciclib—allowed for abemaciclib dose reductions to proactively manage adverse events. Now in an exploratory analysis, researchers investigated the effects of these dose reductions on adjuvant abemaciclib’s efficacy. The data showed that the estimated 4-year invasive disease-free survival rates were generally consistent among the dose-intensity subgroups, suggesting that that the efficacy of adjuvant abemaciclib was not compromised by protocol-mandated dose reductions for this patient group.  

npj Breast Cancer
Advertisement
News & Literature Highlights

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Cancer Letters

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

Future Oncology

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

Advertisement
Advertisement